Hunter Syndrome Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

The Hunter Syndrome Treatment Market is Segmented by Treatment Type (Enzyme Replacement Therapy (ERT), Hematopoietic Stem Cell Transplant (HSCT), and Other Treatment Types), End User (Hospitals, Diagnostic Centers, and Other End Users), and Geography (North America, Europe, Asia-Pacific, and Rest of the World). The report offers the value (in USD million) for the above segments.

Hunter Syndrome Treatment Market Size

 Hunter Syndrome Treatment Market Summary
Study Period: 2020-2028
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5.2 %

Major Players

 Hunter Syndrome Treatment Market Major Players

*Disclaimer: Major Players sorted in no particular order


Need a report that reflects how COVID-19 has impacted this market and it's growth?

Hunter Syndrome Treatment Market Analysis

The hunter syndrome treatment market is expected to be valued at USD 1,265 million, at a CAGR of nearly 5.2%, during the forecast period.

The COVID-19 pandemic impacted the growth of the hunter syndrome market. For instance, according to a study published in BMC, in September 2021, lysosomal storage diseases (LSDs), including mucopolysaccharidosis II (MPS II, hunter syndrome), and others have shown that COVID-19 negatively impacted LSD patients' access to continuous care and therapy. The risk of getting COVID-19 was higher in patients with LSDs than in the general population. As per a study published in BMC, in October 2021, about 20% of patients receiving enzyme replacement therapy (ERT) in a hospital setting experienced treatment disruptions due to the COVID-19 pandemic. Thus, the delayed treatment services impacted the market's growth during the pandemic. However, the market started to recover in the later phases of the pandemic, which was reflected in the rising number of product developments and product approvals. For instance, in January 2021, GC Pharma received Japanese manufacturing and marketing approval for a Hunterase ICV (intracerebroventricular) injection of 15 mg as a treatment for mucopolysaccharidosis type II (hunter syndrome).

Certain factors that are attributing to the market's growth are increasing government initiatives, the introduction of novel therapies, and robust pipelines for treating hunter syndrome.

The rising burden of hunter diseases and the increasing patient population led to a rise in R&D and drug discovery, which is expected to increase the market's growth over the forecast period. For instance, in September 2021, Takeda Pharmaceuticals entered an exclusive collaboration and license agreement with JCR Pharmaceuticals to commercialize JR-141, an investigational next-generation recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase (IDS) enzyme for the treatment of Hunter syndrome. Under the terms of the agreement, Takeda commercialized JR-141 outside of the United States, including Canada, Europe, and other regions (excluding Japan and certain other Asia-Pacific countries). JCR received an upfront payment for such an ex-US license and is eligible to receive additional development and commercial milestones, as well as tiered royalties on potential sales. Such developments are expected to increase the availability of drugs and therapies in the market, thus boosting its growth over the forecast period.

The growing focus on conducting various R&D activities by companies to launch new products for treating hunter diseases is also contributing to the market's growth. For instance, in September 2022, ROBIO Inc. announced that the UK MHRA, Research Ethics Committee (REC), and Health Research Authority (HRA) approved AVROBIO's collaborators for the initiation of the Phase 1/2 clinical trial of investigational autologous hematopoietic stem cell (HSC) gene therapy in infants diagnosed with neuronopathic mucopolysaccharidosis/hunter disease.

The increasing government and organization focus on adopting various strategies such as collaborations and partnerships for developing effective drugs and treatment options are contributing to the growth of the market. For instance, in June 2022, the National MPS Society and Genetic Alliance partnered with Luna to accelerate the development of therapies for treating hunter syndrome in patients. In December 2021, the National MPS Society, Luna, and Genetic Alliance launched a digital drug discovery community in partnership with Takeda Pharmaceutical Company Limited to advance the development of therapeutic interventions for patients with mucopolysaccharidosis type II (MPS II), also known as hunter syndrome.

Therefore, owing to such developments, the market is expected to grow over the forecast period. However, the high treatment costs are likely to impede the market's growth over the forecast period.

Hunter Syndrome Treatment Industry Segmentation

As per the scope of the report, hunter syndrome, also known as mucopolysaccharidosis II or MPS II, is a type of rare disease caused by a lysosomal enzyme or iduronate-2-sulfatase enzyme deficiency. Enzyme replacement therapy (ERT) and hematopoietic stem cell transplant (HSCT) are the two main types of treatment that focus on providing symptomatic relief and managing complications associated with the disease. 

The hunter syndrome treatment market is segmented by treatment type (enzyme replacement therapy (ERT), hematopoietic stem cell transplant (HSCT), and other treatment types), end user (hospitals, diagnostic centers, and other end users), and geography (North America, Europe, Asia-Pacific, and Rest of the World). The report offers the value (in USD million) for the above segments.

By Treatment Type
Enzyme Replacement Therapy (ERT)
Hematopoietic Stem Cell Transplant (HSCT)
Other Treatment Types
By End User
Diagnostic Centers
Other End Users
By Geography
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Rest of the World

Report scope can be customized per your requirements. Click here.

Hunter Syndrome Treatment Market Trends

This section covers the major market trends shaping the Hunter Syndrome Treatment Market according to our research experts:

The Enzyme Replacement Therapy (ERT) Segment is Expected to Witness Significant Growth in the Hunter Syndrome Treatment Market During the Forecast Period

The enzyme replacement therapy is expected to witness significant growth in the hunter syndrome treatment market over the forecast period due to the rising availability of enzyme replacement therapies, increasing awareness, and less stringent guidelines for rare diseases.

Enzyme replacement therapy (ERT) is a standard of care for several types of rare diseases and consists of replacing the deficient or absent enzyme with a functional recombinant version through intravenous administration. For instance, as per an article published in October 2021, it has been observed that pabinafusp alfa was effective against both the somatic and CNS symptoms of patients with MPS-II as it can pass through the blood-brain barrier to reach the central nervous tissues. Thus, the high efficacy and safety of the novel enzyme drug are expected to increase its adoption for treating patients with hunter syndrome, thereby propelling the market's growth.

As per an article published in PLOS One, in May 2021, it has been observed that enzyme replacement therapy (ERT) is the primary treatment for mucopolysaccharidosis type-II (hunter syndrome) that helps in improving the course of diseases by reducing the somatic symptoms, including hepatomegaly and splenomegaly. In addition, as per the same source, ERT using human recombinant iduronate 2-sulphatase administered intravenously is considered the current standard of care for patients with hunter syndrome. Thus, such studies are expected to increase the demand for ERT and propel the segment's growth over the forecast period.

The growing development of enzyme replacement therapy products by companies are also likely to increase the availability of ERT therapies in the market, further augmenting its growth. For instance, in March 2021, the MHLW approved IZCARGO (pabinafusp alfa 10 mL, intravenous drip infusion) for the treatment of MPS II in Japan. It is a recombinant iduronate-2-sulfatase enzyme replacement therapy (ERT) developed using J-Brain Cargo, a proprietary technology developed by JCR, to deliver therapeutics across the blood-brain barrier (BBB).

Thus, owing to the high efficacy and safety of ERT, the rising number of research studies, and increasing product approvals, the studied segment is expected to grow over the forecast period.

Total Active Hunter Syndrome Clinical Trials (in Munber), By Phase, Global, As of November 2022

North America is Expected to Hold a Significant Share in the Hunter Syndrome Treatment Market During the Forecast Period

North America is expected to witness healthy growth over the forecast period due to the rising awareness regarding rare diseases, favorable regulations for orphan drug development, growing healthcare expenditure, and favorable reimbursement policies for expensive drugs in the region. The presence of well-established healthcare infrastructure, increasing adoption of novel therapies, and technological advancements are also expected to fuel the hunter syndrome treatment market.

The increasing focus on developing advanced products by companies and rising product launches and approvals in the region are expected to boost the market over the forecast period. For instance, in August 2022, REGENXBIO Inc. announced its plans to file a Biologics License Application (BLA) in 2024 using the FDA's accelerated approval pathway for RGX-121 for the treatment of mucopolysaccharidosis Type II (MPS II). In February 2022, Homology Medicines, Inc. presented data on HMI-203 gene therapy candidate for the treatment of hunter syndrome (MPS II), under phase I dose-escalation clinical study in adults with hunter syndrome, at the Annual WorldSymposium Meeting.

The increasing focus of key players in conducting clinical trials for evaluating the safety and effectiveness of enzyme drugs and therapies for treating patients with hunter syndrome may also contribute to the market's growth. For instance, as per, as of September 2022, REGENXBIO Inc. was conducting a phase II/III clinical study to determine the safety and efficacy of RGX-121, a gene therapy, in children aged five and over with severe MPS II. As per the same source, 23 active clinical studies for hunter syndrome are ongoing in the United States, out of which nine are in phase I clinical trials, 10 in phase II, three in phase III, and one in phase IV. Hence, the high number of clinical trials in the country may boost the growth of the hunter syndrome treatment market over the forecast period.

The rising focus on developing various safe treatment options for patients with hunter syndrome and increasing product launches in the country are expected to boost the market's growth during the forecast period.

Hunter Syndrome Treatment Market - Growth Rate by Region

Hunter Syndrome Treatment Industry Overview

The hunter syndrome treatment market is moderately competitive and consists of several major players. The companies are focusing on adopting various key strategies such as collaborations, partnerships, product launches, product approvals, and other strategies to withhold their market positions. Some of the companies currently dominating the market are REGENXBIO Inc., Takeda Pharmaceutical Company Limited, Clinigen Group PLC, JCR Pharmaceuticals, ArmaGen, Sangamo Therapeutics, Denali Therapeutics Inc., Bioasis Technologies Inc., Inventiva, etc.

Hunter Syndrome Treatment Market Leaders


  2. Clinigen Group plc

  3. JCR Pharmaceuticals

  4. ArmaGen

  5. Takeda Pharmaceutical Company Limited (Shire)

*Disclaimer: Major Players sorted in no particular order

Hunter Syndrome Treatment Market - cl.png

Hunter Syndrome Treatment Market News

  • In July 2022, Avrobio introduced AVR-RD-05, a gene therapy that has gained orphan drug designation from the USFDA to treat mucopolysaccharidosis type II.
  • In February 2022, Denali Therapeutics Inc. presented new longer-term data from an ongoing phase 1/2 clinical trial of DNL310, an investigational brain-penetrant enzyme replacement therapy intended to treat both the central nervous system and peripheral manifestations of MPS II (hunter syndrome), at World Symposium.

Hunter Syndrome Treatment Market Report - Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Government Initiatives

      2. 4.2.2 Introduction of Novel Therapies

      3. 4.2.3 Robust Pipelines

    3. 4.3 Market Restraints

      1. 4.3.1 High Treatment Costs

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 5.1 By Treatment Type

      1. 5.1.1 Enzyme Replacement Therapy (ERT)

      2. 5.1.2 Hematopoietic Stem Cell Transplant (HSCT)

      3. 5.1.3 Other Treatment Types

    2. 5.2 By End User

      1. 5.2.1 Hospitals

      2. 5.2.2 Diagnostic Centers

      3. 5.2.3 Other End Users

    3. 5.3 By Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Rest of the World


    1. 6.1 Company Profiles

      1. 6.1.1 REGENXBIO Inc.

      2. 6.1.2 Takeda Pharmaceutical Company Limited

      3. 6.1.3 Triley Bidco Limited (Clinigen Group PLC)

      4. 6.1.4 JCR Pharmaceuticals

      5. 6.1.5 Sangamo Therapeutics

      6. 6.1.6 Denali Therapeutics Inc.

      7. 6.1.7 Bioasis Technologies Inc.

      8. 6.1.8 Inventiva

      9. 6.1.9 GC Pharma (Green Cross Holdings)

      10. 6.1.10 Esteve

      11. 6.1.11 Avrobio Inc.

      12. 6.1.12 CANbridge Life Sciences Ltd

    2. *List Not Exhaustive

**Subject to Availability
Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments
You can also purchase parts of this report. Do you want to check out a section wise price list?

Hunter Syndrome Treatment Market Research FAQs

The Hunter Syndrome Treatment Market market is studied from 2020 - 2028.

The Hunter Syndrome Treatment Market is growing at a CAGR of 5.2% over the next 5 years.

The Hunter Syndrome Treatment Market is valued at 942 Million USD in 2020.

The Hunter Syndrome Treatment Market is valued at 1265 Million USD in 2028.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2022.

REGENXBIO Inc., Clinigen Group plc, JCR Pharmaceuticals, ArmaGen, Takeda Pharmaceutical Company Limited (Shire) are the major companies operating in Hunter Syndrome Treatment Market.

Hunter Syndrome Treatment Industry Report

Statistics for the 2023 Hunter Syndrome Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Hunter Syndrome Treatment analysis includes a market forecast outlook to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!